查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470939

疫苗佐剂市场：分产品、给药途径、疾病和应用 - 全球预测 2024-2030

Vaccine Adjuvants Market by Product (Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants), Route of Administration (Intradermal, Intramuscular, Intranasal), Disease, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年疫苗佐剂市场规模为8.2565亿美元，预计2024年将达8.8418亿美元，2030年将达到14.042亿美元，复合年增长率为7.88%。

疫苗佐剂是疫苗製剂的重要组成部分，可增强和调节疫苗中所含抗原引发的免疫反应。疫苗佐剂包括铝盐、油乳剂、皂素、细胞激素、 类铎受体致效剂等多种产品。疫苗佐剂有多种应用，包括感染疾病、癌症免疫治疗、过敏治疗、自体免疫疾病管理和兽医学。开拓市场成长要素包括由于公众对预防医学的认识不断提高而导致对有效疫苗的需求增加、政府和私人公司对研发活动的投资增加以及新兴市场的有利报销政策。此外，新的疫苗接种技术，例如基于 mRNA 的方法，预计将推动对有效佐剂的需求。与学术机构和小型生物技术公司合作进行新型佐剂研究，推出针对特定免疫机制的创新佐剂来解决未满足的临床需求，将为疫苗佐剂市场带来巨大的前景。然而，市场面临严格的监管流程、高昂的开发和製造成本、与某些助剂相关的潜在安全问题以及导致竞争加剧和报酬率下降的专利到期等限制。优化佐剂功效和安全性组合的挑战可能会抑制采用率。

主要市场统计
基准年[2023] 8.2565亿美元
预测年份 [2024] 88418万美元
预测年份 [2030] 1,404.2 百万美元
复合年增长率（%） 7.88%

疫苗佐剂的使用激增以提高癌症疫苗的功效

在肿瘤学中，疫苗佐剂旨在增强针对肿瘤抗原的免疫反应，提高癌症疫苗的功效，而癌症相关佐剂与肿瘤抗原结合，特异性激发抗肿瘤免疫。疫苗佐剂用于感染疾病，以增强疫苗对病毒、细菌和寄生虫的效力。感染疾病的疫苗佐剂主要着重于预防而非治疗。这些佐剂刺激更广泛的免疫反应，包括体液和细胞介导的免疫。此外，这些佐剂已在大规模免疫宣传活动中进行了广泛测试，并表现出既定的安全性。

产品 免疫系统受损的患者越来越青睐佐剂乳剂

佐剂乳液是油和水的混合物，充当抗原的疫苗载体。佐剂乳剂透过更好地将抗原递送至免疫细胞来增强免疫反应。乳液因其稳定性、多功能性和易于製造而受到优选。合併佐剂是使用两种或两种以上不同类型的佐剂，利用协同效应来提高疫苗製剂中抗原的整体免疫抗原性。当单组分佐剂单独无法提供最佳免疫反应时，通常会采用此方法。矿物质佐剂基于铝盐和磷酸钙等化合物，它们充当储库形成剂，增强呈现抗原并延长免疫反应。颗粒佐剂由奈米颗粒或微粒组成，可以有效地递送抗原，透过模仿病原体的结构来刺激先天性和适应性免疫。这些佐剂通常用于针对特定病原体或癌细胞。

人类用疫苗中疫苗佐剂的使用增加

人类佐剂包括有效且安全的标靶疫苗，用于对抗感染疾病、癌症和其他健康状况。佐剂在人类疫苗中的使用已显着扩大，因为它们能够增强免疫反应，从而节省剂量并减少所需抗原的量，从而实现具有成本效益的疫苗生产。佐剂在兽用疫苗中发挥重要作用，可预防和控制动物感染疾病，确保食品安全、公共卫生和动物整体福祉。兽用佐剂的偏好是基于功效、安全性、免疫抗原性、与抗原的生物相容性、易用性和稳定性。

给药途径：透过皮内给药扩大疫苗佐剂的使用

皮内注射涉及将疫苗佐剂直接注射到皮肤中，从而产生有针对性的局部免疫反应。这种方法对于需要细胞介导的固态免疫的疫苗特别有效，例如卡介苗（BCG）和某些流感疫苗。肌肉注射是刺激强大的全身免疫反应的有效方法，适用于大多数疫苗，包括B型肝炎和人类乳突病毒 (HPV)。鼻内给药透过鼻黏膜输送疫苗佐剂，促进局部黏膜免疫反应，以防止空气传播的病原体。口服疫苗佐剂透过摄取或舌下吸收诱导全身和黏膜免疫。此途径适用于轮状病毒等肠道病原体，具有给药方便、提高病患依从性的优点。皮下注射将疫苗沉积在皮下，以延长抗原暴露时间并增强免疫反应，当肌肉注射有风险或需要缓释性机制时使用。

区域洞察

美洲的疫苗佐剂市场正在发展，对增强免疫反应的创新佐剂的需求很高。美国政府正大力投资研究倡议，以支持佐剂的开发。欧盟 (EU) 由于其成熟的医疗基础设施和正在进行的临床试验，显示出疫苗佐剂的巨大成长潜力。在中东，一些国家正在政府和非政府组织的支持下积极加强免疫计画。非洲地区疫苗佐剂的成长得益于国际组织、政府和非政府组织对免疫计画的资助增加。由于对先进疫苗技术的投资，亚太地区的疫苗佐剂市场正在成长。鑑于开发新型疫苗技术的重点，疫苗佐剂的使用预计也将在全球最终用途领域扩大。

FPNV定位矩阵

FPNV定位矩阵对于评估疫苗佐剂市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对疫苗佐剂市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.疫苗佐剂市场规模及预测如何？

2.疫苗佐剂市场预测期间需要考虑投资的产品、区隔市场、应用和领域有哪些？

3.疫苗佐剂市场的技术趋势和法规结构是什么？

4.疫苗佐剂市场主要厂商的市场占有率是多少？

5.进入疫苗佐剂市场的合适业态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病和通用感染疾病的发生率增加
      • 需要提高疫苗的有效性
      • 畜牧业的扩张和相关疾病的传播
    • 抑制因素
      • 矿物佐剂与重组蛋白及次单位疫苗的不相容性
    • 机会
      • 复合佐剂的潜力不断增长
      • 扩大疫苗开发
    • 任务
      • 资本集中且耗时的开发与核准流程
  • 市场区隔分析
    • 疾病：使用疫苗佐剂提高癌症疫苗效力激增
    • 产品：佐剂乳剂在免疫力较弱的人中越来越受欢迎。
    • 应用：增加人类疫苗中疫苗佐剂的使用
    • 给药途径：透过皮内给药增加疫苗佐剂的使用
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章疫苗佐剂市场：副产品

  • 佐剂乳剂
  • 复方佐剂
  • 矿物佐剂
  • 颗粒佐剂

第七章疫苗佐剂市场：途径

  • 皮内
  • 肌肉注射
  • 鼻内
  • 口服
  • 皮下的

第八章疫苗佐剂市场：依疾病分类

  • 癌症
  • 感染疾病

第九章疫苗佐剂市场：依应用分类

  • 人类
  • 动物

第十章 美洲疫苗佐剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太疫苗佐剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲疫苗佐剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 普利兹克分子工程学院与工业界合作开发下一代疫苗
    • Croda Partners 疫苗佐剂
    • 牛津大学开发的 R21/Matrix M 疟疾疫苗获准在加纳使用
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-02026C4C8667

[183 Pages Report] The Vaccine Adjuvants Market size was estimated at USD 825.65 million in 2023 and expected to reach USD 884.18 million in 2024, at a CAGR 7.88% to reach USD 1,404.20 million by 2030.

Vaccine adjuvants are essential components in the formulation of vaccines, which enhance and modulate the immune response elicited by the antigen present in the vaccine. The vaccine adjuvants encompass various products, including aluminum salts, oil emulsions, saponins, cytokines, and toll-like receptor agonists. The vaccine adjuvants have diverse applications, such as infectious diseases, cancer immunotherapy, allergy treatment, autoimmune disorders management, and veterinary medicine. Growth factors driving the market include growing demand for effective vaccines due to heightened public awareness about preventive healthcare measures, rising investments from governments and private entities for research & development activities, and favorable reimbursement policies in developed markets. Additionally, novel vaccination technologies such as mRNA-based approaches are anticipated to boost demand for effective adjuvants. Partnering with academic institutes or smaller biotechnology companies for novel adjuvant research and introduction of innovative adjuvants targeting specific immune mechanisms and addressing unmet clinical needs offers substantial prospects for the vaccine adjuvant market. However, the market faces limitations such as stringent regulatory processes, high development & manufacturing costs, potential safety concerns associated with specific adjuvants, and patent expirations leading to increased competition and reduced profit margins. The challenges in optimizing adjuvant combinations for efficacy and safety may impede adoption rates.

KEY MARKET STATISTICS
Base Year [2023] USD 825.65 million
Estimated Year [2024] USD 884.18 million
Forecast Year [2030] USD 1,404.20 million
CAGR (%) 7.88%

Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines

In oncology, vaccine adjuvants enhance the immune response against tumor antigens, aiming to increase the efficacy of cancer vaccines, and cancer-related adjuvants are combined with tumor antigens to stimulate anti-tumor immunity specifically. Vaccine adjuvants have been utilized in infectious diseases to boost vaccine efficacy against viruses, bacteria, and parasites. Infectious disease vaccine adjuvants primarily focused on prevention rather than therapy. These adjuvants stimulate a broader immune response, including humoral and cellular immunity. Additionally, these adjuvants have been extensively tested in mass vaccination campaigns and exhibit an established safety profile.

Product: Increasing preference for adjuvant emulsions for those with compromised immune systems

Adjuvant emulsions are mixtures of oil and water that serve as a vaccine carrier for antigens. These emulsions enhance the immune response by delivering better antigens to immune cells. They are preferred due to their stability, versatility, and ease of production. Combination adjuvants use two or more different types of adjuvants to leverage synergistic effects for enhancing the overall immunogenicity of antigens within a vaccine formulation. This approach is usually employed when single-component adjuvants may not provide optimal immune responses alone. Mineral adjuvants are based on compounds like aluminum salts or calcium phosphate, which serve as depot-forming agents to enhance antigen presentation and prolong the immune response. Particulate adjuvants consist of nano or microparticles that can effectively deliver antigens and stimulate innate and adaptive immunity by mimicking the pathogen's structure. These adjuvants are usually employed when targeting specific pathogens or cancer cells.

Application: Increasing use of vaccine adjuvants for human vaccines

The human adjuvant has effective, safe, and targeted vaccines to combat infectious diseases, cancer, and other health conditions. The application of adjuvants in human vaccines has grown significantly due to their ability to enhance immune responses, allowing dose sparing and reducing the amount of antigen needed, which leads to cost-effective vaccine production. Adjuvants play a crucial role in veterinary vaccines to prevent and control infectious disorders in animals, ensuring food safety, public health, and overall animal welfare. Preferences for veterinary adjuvants are based on efficacy, safety, immunogenicity, biocompatibility with antigens, ease of use, and stability.

Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration

Intradermal administration involves the injection of the vaccine adjuvant directly into the skin, allowing for a targeted and localized immune response. This method is particularly effective for vaccines that require cell-mediated solid immunity, such as Bacille Calmette-Guerin (BCG) and certain influenza vaccines. The intramuscular route provides an efficient means to stimulate a robust systemic immune response suitable for most vaccines, including Hepatitis B and human papillomavirus (HPV). Intranasal administration involves delivering the vaccine adjuvant through the nasal mucosa, promoting a local mucosal immune response to protect against airborne pathogens - ideal for respiratory infections such as influenza. Oral administration of vaccine adjuvants employs ingestion or sublingual absorption to induce systemic and mucosal immunity. This route is preferred for enteric pathogens, such as rotavirus, and offers advantages, providing ease of administration and improved patient compliance. Subcutaneous injections deposit the vaccine beneath the skin for prolonged antigen exposure and enhanced immune response, used when intramuscular injection might pose risks or require slow-release mechanisms.

Regional Insights

The vaccine adjuvants market is evolving in the Americas with a high demand for innovative adjuvants to enhance immune responses. The U.S. government is investing heavily in research initiatives to support adjuvant discovery. The European Union represents substantial growth potential for vaccine adjuvants due to its well-established healthcare infrastructure and ongoing clinical trials. In the Middle East, several nations are actively boosting their immunization programs with assistance from government and non-governmental organizations. The African region's growth in vaccine adjuvants can be attributed to increased funding for immunization programs by international organizations, governments, and NGOs. The vaccine adjuvants market is growing in the APAC region owing to investments in advanced vaccine technologies. Besides, emphasis on the development of novel vaccine technologies is anticipated to boot the use of vaccine adjuvants across the end-use sectors globally.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaccine Adjuvants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccine Adjuvants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Adjuvants Market, highlighting leading vendors and their innovative profiles. These include Agenus Inc., Aphios Corporation, Bioveta, A.S., Croda International PLC, CSL Limited, Dynavax Technologies Corporation, GlaxoSmithKline PLC, Hayashibara Co., Ltd. by NAGASE & CO., LTD., InvivoGen, Merck KGaA, Novavax, Inc., OZ Biosciences SAS, Pacific GeneTech Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vaccine Adjuvants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Adjuvant Emulsions
    • Combination Adjuvants
    • Mineral Adjuvants
    • Particulate Adjuvants
  • Route of Administration
    • Intradermal
    • Intramuscular
    • Intranasal
    • Oral
    • Subcutaneous
  • Disease
    • Cancer
    • Infectious Diseases
  • Application
    • Human
    • Veterinary
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaccine Adjuvants Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccine Adjuvants Market?

3. What are the technology trends and regulatory frameworks in the Vaccine Adjuvants Market?

4. What is the market share of the leading vendors in the Vaccine Adjuvants Market?

5. Which modes and strategic moves are suitable for entering the Vaccine Adjuvants Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of infectious and zoonotic diseases
      • 5.1.1.2. Need to increase the effectiveness of vaccines
      • 5.1.1.3. Growth in livestock operations and prevalence of associated diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising potential of combination adjuvants
      • 5.1.3.2. Increasing development of vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Capital-intensive and time-consuming development and approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines
    • 5.2.2. Product: Increasing preference for adjuvant emulsions for those with compromised immune systems
    • 5.2.3. Application: Increasing use of vaccine adjuvants for human vaccines
    • 5.2.4. Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Vaccine Adjuvants Market, by Product

  • 6.1. Introduction
  • 6.2. Adjuvant Emulsions
  • 6.3. Combination Adjuvants
  • 6.4. Mineral Adjuvants
  • 6.5. Particulate Adjuvants

7. Vaccine Adjuvants Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intradermal
  • 7.3. Intramuscular
  • 7.4. Intranasal
  • 7.5. Oral
  • 7.6. Subcutaneous

8. Vaccine Adjuvants Market, by Disease

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Infectious Diseases

9. Vaccine Adjuvants Market, by Application

  • 9.1. Introduction
  • 9.2. Human
  • 9.3. Veterinary

10. Americas Vaccine Adjuvants Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaccine Adjuvants Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaccine Adjuvants Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Pritzker School of Molecular Engineering enters Academic-Industry partnership to create Next Generation vaccines
    • 13.3.2. Croda Partners on Vaccine Adjuvants
    • 13.3.3. R21/Matrix-M Malaria Vaccine Developed By University Of Oxford Receives Regulatory Clearance For Use In Ghana
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. VACCINE ADJUVANTS MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINE ADJUVANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. VACCINE ADJUVANTS MARKET DYNAMICS
  • FIGURE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINE ADJUVANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ADJUVANT EMULSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ADJUVANT EMULSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COMBINATION ADJUVANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COMBINATION ADJUVANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MINERAL ADJUVANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MINERAL ADJUVANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATE ADJUVANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATE ADJUVANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRADERMAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HUMAN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HUMAN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VETERINARY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 354. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY VACCINE ADJ